On 2025-10-02, the FDA approved a supplemental application for Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs). This approval, designated as BLA 761347 S-3, was based on efficacy data for the drug.
Background
Atezolizumab, marketed as Tecentriq Hybreza, is the drug for which this supplemental application was approved. The supplemental application specifically focused on efficacy, indicating a review of data supporting the drug's effectiveness. Tecentriq Hybreza is a combination product containing atezolizumab and hyaluronidase-tqjs.
What this means
The FDA's approval of this supplemental application for Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) on 2025-10-02 signifies a regulatory update regarding its demonstrated efficacy. Supplemental applications are submitted to the FDA to propose changes to an already approved product, such as a new indication, a new dosage, or updated manufacturing processes. In this case, the approval specifically pertains to efficacy, indicating that new data or analyses have been reviewed and accepted by the agency, further supporting the drug's effectiveness. This type of update provides clinicians with additional validated information for prescribing decisions and may impact patient access or treatment guidelines for conditions where Tecentriq Hybreza is applicable.
Source
The information regarding this supplemental approval was sourced from the FDA. The approval of the supplemental application BLA 761347 S-3 for Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) was recorded on 2025-10-02 on accessdata.fda.gov.